Pfizer announces Talzenna and Xtandi combination data from phase 3 study
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
Through this collaboration, the erstwhile Government Maternity Hospital in Kanakapura Taluk has been rebuilt and the new hospital has facilities including oxygen and medical gas pipelines
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Investment proposals to the tune of Rs. 54,000 crore has been received in the healthcare and Rs. 17,000 crore has been received in medical education sector
The Ministry of Ayush endeavour is to get entry level NABH certification for 12,500 Ayush Wellness Centers by the end of 2023
To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
Technology and innovation play a pivotal role towards enhancing healthcare systems, increasing access to healthcare services, and reducing costs of therapies and consultations
Subscribe To Our Newsletter & Stay Updated